Literature DB >> 31679863

Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.

Gloria Ikilezi1, Orvalho J Augusto2, Joseph L Dieleman3, Kenneth Sherr2, Stephen S Lim3.   

Abstract

Donor assistance for immunization has remained resilient with increased resource mobilization efforts in recent years to achieve current global coverage targets. As a result, more countries continue to introduce new vaccines while optimizing coverage for traditional vaccines. Gavi the Vaccine Alliance has been at the forefront of immunization support specifically among low and middle income countries, alongside other channels of development assistance which continue to play a vital role in immunization. Using available recipient country level data from 1996 to 2016, we estimate the impact of Gavi support for vaccines and health systems strengthening on vaccine coverage for 3 dose DPT, 3 dose pneumococcal conjugate vaccine, 3 dose pentavalent, 2 dose measles and 2 dose rotavirus vaccines. We investigate the same effects of total aid for immunization from other channels of development assistance. Standard time series cross sectional analysis methods are applied to investigate the effects of vaccine support controlling for country income, governance and population, with robustness tests implemented using different model specifications. Double counting was eliminated and results are presented in real 2017 US dollars. We found significant positive effects of aid particularly among the newer vaccines. Using 2016 country specific disbursements and coverage levels as baseline, we estimated that among recipient countries below the universal target, additional DAH per capita required to reach 90%, ranged from 0.01USD to 4.33USD for PCV, 0.03USD to 9.06USD for pentavalent vaccine and 0.01USD to 2.57USD for rotavirus vaccine. The estimated number of children vaccinated through 2016, attributable to Gavi support totaled 46.6million, 75.2million and 12.3million for PCV, pentavalent and rotavirus vaccines respectively. Our analysis suggests substantial success both from a historical and prospective perspective in the implementation of global immunization initiatives thus far. As more vaccines are rolled out and countries transition from donor aid, strategies for fiscal sustainability and efficiency need to be strengthened in order to achieve universal immunization coverage.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Development assistance for health; GVAP; Gavi; Recipient countries; Universal immunization coverage; Vaccine

Year:  2019        PMID: 31679863     DOI: 10.1016/j.vaccine.2019.10.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Fairer financing of vaccines in a world living with COVID-19.

Authors:  Itamar Megiddo; Justice Nonvignon; Richmond Owusu; Kalipso Chalkidou; Abigail Colson; Mohamed Gad; Petra Klepac; Francis Ruiz; Alec Morton
Journal:  BMJ Glob Health       Date:  2020-07

2.  Willingness of Caregivers to Have Their Children Vaccinated with Pneumococcal Vaccines in the Context of an Innovative Immunization Strategy - Weifang City, Shandong Province, 2021.

Authors:  Yuan Yang; Ting Zhang; Yan Wang; Libing Ma; Shuyun Xie; Jian Zhou; Weiran Qi; Qing Wang; Peixi Dai; Yuanze Du; Luzhao Feng; Chunping Wang; Weizhong Yang
Journal:  China CDC Wkly       Date:  2022-05-20

Review 3.  Advancing sustainable development goals through immunization: a literature review.

Authors:  Catherine Decouttere; Kim De Boeck; Nico Vandaele
Journal:  Global Health       Date:  2021-08-26       Impact factor: 4.185

4.  Equal access of COVID-19 vaccine distribution in Africa: Challenges and way forward.

Authors:  Abdullahi T Aborode; Oluwatosin A Olofinsao; Ekwebelem Osmond; Abiokpoyanam P Batubo; Omowonuola Fayemiro; Onigbinde Sherifdeen; Luqman Muraina; Babatunde S Obadawo; Shoaib Ahmad; Emmanuel A Fajemisin
Journal:  J Med Virol       Date:  2021-05-28       Impact factor: 20.693

5.  Mapping routine measles vaccination in low- and middle-income countries.

Authors: 
Journal:  Nature       Date:  2020-12-16       Impact factor: 69.504

6.  Integrating pharmaceutical systems strengthening in the current global health scenario: three 'uncomfortable truths'.

Authors:  Tamara Hafner; Marlon Banda; Jillian Kohler; Zaheer-Ud-Din Babar; Murray Lumpkin; Mojisola Christianah Adeyeye; Emmanuel Nfor; Francis Aboagye-Nyame; Javier Guzman
Journal:  J Pharm Policy Pract       Date:  2020-06-25

7.  Editorial: Molecular Vaccines Against Pathogens in the Post-genomic Era.

Authors:  Angel Alejandro Oñate; Yanmin Wan; Alberto Moreno
Journal:  Front Cell Infect Microbiol       Date:  2020-01-22       Impact factor: 5.293

8.  Uganda's increasing dependence on development partner's support for immunization - a five year resource tracking study (2012 - 2016).

Authors:  Carol Kamya; Christabel Abewe; Peter Waiswa; Gilbert Asiimwe; Faith Namugaya; Charles Opio; Immaculate Ampeire; Stephen Lagony; Charlotte Muheki
Journal:  BMC Public Health       Date:  2021-01-19       Impact factor: 3.295

9.  Filling the gaps in the global prevalence map of clinical antimicrobial resistance.

Authors:  Rik Oldenkamp; Constance Schultsz; Emiliano Mancini; Antonio Cappuccio
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-05       Impact factor: 11.205

10.  Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D.

Authors:  Marga Janse; Thomas Brouwers; Eric Claassen; Peter Hermans; Linda van de Burgwal
Journal:  Front Public Health       Date:  2021-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.